Back to search

University of British Columbia

Characterization of programmed death ligands in B-cell non-Hodgkin lymphomas

Abstract

dc:description

Non-Hodgkin lymphomas constitute a conglomerate of malignancies that originate from a population of white blood cells termed lymphocytes. Lymphoid cancers are a significant health burden in Canada, with over 9,200 new diagnoses in 2018. Of those newly diagnosed, roughly 40% will die within five years. Studying a subpopulation of aggressive B-cell derived non-Hodgkin lymphomas with both high-throughput sequencing and conventional research techniques, we identified recurrent, somatic aberrations in two genes that are contributors to lymphoma pathogenesis: programmed death ligands 1 (CD274) and 2 (PDCD1LG2). In healthy individuals, programmed death ligands are central to maintaining peripheral tolerance and preventing autoimmune disease. However, we establish that malignant B-cells hijack this axis to suppress the antitumor immune response.Within this dissertation, we report on the frequency of programmed death ligand structural genomic rearrangements in seven different B-cell lymphoma entities and demonstrate the effects of structural genomic rearrangements on gene expression. Additionally, we evaluate ectopic cytokine stimulation, copy number variations, DNA methylation, and micro RNA regulation as additional mechanisms of deregulating programmed death ligand expression. Using novel, capture-based high-throughput techniques, we characterize, at base-pair resolution, the subtypes, cluster locations, and partners of programmed death ligand structural genomic rearrangements. We go on to demonstrate the effects of protein expression and characterize the functional impairment resulting from deregulated programmed death ligand binding in both B and T-cell populations using retroviral cell line models. Finally, in evaluating flanking breakpoint sequences of programmed death ligand structural genomic rearrangements, we propose the molecular mechanisms involved in producing these aberrations. Taken together, our work informs on relevant components of B-cell non-Hodgkin lymphoma pathogenesis and substantiates the effectiveness of molecularly precise therapies targeting the programmed death ligand axis, as they become mainstays of lymphoma treatment.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Pathology and Laboratory Medicine
Grantor dc:publisher
University of British Columbia
Year dc:date
2020

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Twa, David D. W.

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/74791

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Twa, David D. W.. Characterization of programmed death ligands in B-cell non-Hodgkin lymphomas. doctoral thesis, University of British Columbia, 2020. http://hdl.handle.net/2429/74791